Opus Genetics, Inc.
IRD
Positions held
Your positionsIRD isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $371.05M | Enterprise value | $318.45M | Trailing P/E | — | Forward P/E | -6.24 |
| PEG | — | Price / book | -28.41 | Beta | 0.62 | Dividend yield | 0.00% |
| Revenue growth | -73.8% | Earnings growth | — | Gross margin | -2.9% | Operating margin | -21.8% |
| Profit margin | 0.0% | ROE | -48.0% | ROA | -48.1% | Debt / equity | — |
| Current ratio | 12.19 | Free cash flow | -$38.56M | Analyst recommendation | strong_buy | Mean target | $13.41 |
| 52w high | $7.07 | 52w low | $1.70 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.8M | $2.2M | $3.9M | $3.1M | $2.9M | — |
| Op margin | -2182.8% | -665.9% | -296.3% | -269.9% | -309.0% | — |
| Net income | -$8.1M | -$65.5M | -$16.5M | -$17.5M | -$7.4M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$16.5M | -$14.4M | -$11.5M | -$8.3M | -$8.9M | — |
- Revenue -65% vs prior quarter ($0.8M vs $2.2M).
- Operating margin compressed to -2182.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | — |
| Op margin | -271.9% | -310.0% | -55.5% | 45.7% | — |
| Net income | -$49.6M | -$57.5M | -$10.0M | $17.9M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$38.6M | -$34.1M | -$10.6M | $18.2M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?
2026-10-05 · FDA Decision Watch: RHHBY, VTRS And IRD Face Key October Drug Rulings As MRK Withdraws Application
2026-09-16 · Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?
2026-09-10 · Wedbush Raises Price Target on Opus Genetics to $13 From $10, Keeps Outperform Rating
2026-09-10 · Correction: Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating
2026-09-10 · Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating
2026-09-09 · Sector Update: Healthcare Stocks Softer Late Afternoon
2026-09-09 · Update: Opus Genetics Shares Rise After Reporting Vision Improvement in Phase 1/2 OPGx-BEST1 Trial
2026-09-09 · Top Midday Gainers
2026-09-09 · IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial
2026-09-09 · Wedbush Raises Opus Genetics Price Target to $13 From $10, Maintains Outperform Rating
2026-09-09 · Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027
Price (daily)
Full chart · RSI · MACD · patterns